Sickle cell disease
Conditions
Interventions
Total sample of 120 individuals, matched for gender and age group. Participants will be divided into four groups: Control (30 participants with sickle cell anemia who will receive both vitamin D and f
OD group (30 participants with sickle cell anemia, who will receive fish oil and vitamin D supplementation)
group O- (30 participants with sickle cell anemia who will receive fish oil supplementation and vitamin D placebo)
group D- (30 participants with sickle cell anemia who will receive vitamin D supplementation and fish oil placebo).
Supplementation of fish oil will be performed in the amount of 1000 mg per gelatin c
C15.378.071.141
G07.203.300.456
Sponsors
Universidade do Estado do Rio de Janeiro
Ministério da Saúde
Eligibility
Age
19 Years to 59 Years
Inclusion criteria
Inclusion criteria: Adults with ages ranging from 19 to 59 years of age; Be homozygous for sickle cell anemia - HbS (SS genotype); Possibility of attendance at periodic laboratory visits and examinations; Be lucid and oriented.
Exclusion criteria
Exclusion criteria: Participants who have had blood transfusions in the last 1 month before the first evaluation; Participants who present an episode of disease exacerbation at the time of the first evaluation; Participants who have taken vitamin D and / or omega-3 supplementation for less than 6 months or at the time of the first evaluation; Have not been hospitalized for less than fifteen days; People with other types of hemoglobinopathies; Use of Hydroxyurea; Pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of the clinical and inflammatory condition. For this, the following parameters will be used: reduction in the number of hospitalizations, reduction in the frequency of pain episodes, reduction in pain intensity, blood count evaluation, lipid profile, C-reactive protein, lactate dehydrogenase, tumor necrosis factor alpha (TNF- a), VCAM, P-selectin, HbS and HbF concentration, indirect oximetry. | — |
Secondary
| Measure | Time frame |
|---|---|
| evaluation of vitamin D levels in patients with sickle cell anemia. Those that are sufficient or deficient according to the measurement of 25 (OH) D will be evaluated, using high performance liquid chromatography coupled with a dioderray detector (HPLC-DAD).;reduction of vaso-occlusive pain crises, through reporting and / or consulting the medical record of the number of hospitalizations before and after supplementation.;improvement of the disposition, through the report of daily activities and tiredness (fatigue) or improvement of the disposition when performing them, before and after the supplementation.;improvement of the hemolytic and vaso-occlusive condition, with evaluation of lactate dehydrogenase and haptoglobin. | — |
Countries
Brazil
Contacts
Public ContactMarta dos Reis
Universidade do Estado do Rio de Janeiro
Outcome results
None listed